{"name":"Trevena Inc.","slug":"trevena-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":16333000,"netIncome":-40289000,"cash":40605000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2020-01-01","label":"Olinvyk first approved","drug":"Olinvyk","drugSlug":"oliceridine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Olinvyk","genericName":"OLICERIDINE","slug":"oliceridine","indication":"Moderate pain","status":"marketed"}]}],"pipeline":[{"name":"Olinvyk","genericName":"OLICERIDINE","slug":"oliceridine","phase":"marketed","mechanism":"Olinvyk works by binding to the mu-type opioid receptor in the brain, which helps to reduce the perception of pain.","indications":["Moderate pain","Severe pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNZ1Q4UjZiVDdkc0FDRkszV19BN1ZudlREN2NKNjRtMG5zUlg5NVFCamFXMEd2b05faDF4YTFqbW1SWUpqelJMNDVHR0RSQVFZUWpodXF3eTR4QjhZaTB0WkFCRzhmeGM4VGd4MmZtQVJLMXVrNFk1dUhKRGFXRVRRRmpoWVNjR1NOTzFsTW54RDRpaDA3bjY0QVVXdktocUU5RTV3THV6NGdZbmN5UjNhUVZkRjQ1Uk5sLTZuekpIcHpWN3NkbWlmZkRoWU9zQVhPbDViVUdVN0JTVkZSdUgyemZLSmt2SnFyaFRsbg?oc=5","date":"2026-04-02","type":"pipeline","source":"Barchart.com","summary":"Chronic and Acute Pain Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Chronic and Acute Pain Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxPMWdMTTRLVnZXYTgzYmtkQ0E2ZlJjQlA4S2s0amJ6OF9uM2VMcFdHdS1fdC1kTWg2alVmUjZlakcwNzJfenpfZmJnckxGZDZBT1Rub0NkTXByazEzREowUDd2NzN0QUhsZHAyVFBNZmxzMUx4MElxRmlpRklqSXlfcmFadjJ4SFhHOEdRUFh2blV5b0N6Y29YaS1QTGliV3NtMGxpYzhFRkozWHB0Uk15YzVpYVQzYXdaajZTMUZtUkZ2U3lzdTg2OUdyR3FlYm9SYXVUU2U4UlFtZ0s0YzlwTVl5VnZTVU9IRnMxYWVlSy1qMWpFa2hyQmFVS215ZS1XbmVTcnlJQXBOeUZ4NHdlNl82RzFEQ29MSkV5ZFEtdTVCU2lMaWF5Qw?oc=5","date":"2026-01-20","type":"trial","source":"GlobeNewswire","summary":"Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: - GlobeNewswire","headline":"Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum:","sentiment":"neutral"},{"date":"2026-01-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPb2tUX3lEcGkwMVFydlFNTEt6WVJDRzBuYUFTaDdPaGF1YzI4Ym9fN0t2RHNmMUdtakREWDdUV3RSY1ZiLXU3aWQ4OU4wQ1pISE16YmxJb3F2UWlZc2pXN1Vmb29fNzFweE9STFp5OFZCOG0zLXhrbmxqV2JGRGluMXBIWUlSYnloU2JJZ1J6UTBLZ1FCc3cwQnZ2UjBKQjZTZllSbEE2TUZDbERjME0zR3FpVUtkQ25ZWndaWGowVWxTamk0UTVSc3N5QjktRl9RYkIyb2h1eTFydw?oc=5","date":"2026-01-08","type":"pipeline","source":"businesswire.com","summary":"Ray Therapeutics Appoints Scott Braunstein, M.D., as Chairman of the Board of Directors - businesswire.com","headline":"Ray Therapeutics Appoints Scott Braunstein, M.D., as Chairman of the Board of Directors","sentiment":"neutral"},{"date":"2025-05-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5YQ3pYeTV2cFJhQzlIbW16Yzl5Ujd5MWNmMS1ldHUzXzZsOXoxbGJNYUkzVmczdEttcXBUNmkyaGhCbE90TXpONXJtdzM3bDE0ZDZB?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"VINC Stock Price, News & Analysis | Vincerx Pharma - Stock Titan","headline":"VINC Stock Price, News & Analysis | Vincerx Pharma","sentiment":"neutral"},{"date":"2025-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPZkl5VjlwVGN3c08yUThral9YazZLVHZuUTNqc1cwUWY2b2NvTWI2VHNkWlo5Ung2M29PQ1pMNkNOWHAwcXB4bDJTQUlLbXNpOFFvUzhvNEhxU2lkMjlRV2YycTlfQWswYk1aN3RBWDYxZE9QelBKZ213TllNcUxoOXNkNkdBZS1Xd3RBODIxQzRxNFF6WXNReU84VmlrWmFYbGc?oc=5","date":"2025-01-15","type":"pipeline","source":"Investing.com","summary":"Trevena discontinues OLINVYK injection sales - Investing.com","headline":"Trevena discontinues OLINVYK injection sales","sentiment":"neutral"},{"date":"2025-01-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-11-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQOXBONWtSNWVPOWJkTU5IZXVxVWh0VlFTbTR2amgxa0xuNWVDdGxXSFFpZWJuNmNFZlNvMzkzQWs5RVdtSUluckx6RnowME14VU9oQ1BpOExocF9xNndNcG54dFRfancyTVl0Q09oUUZwX2JDeldtQlNxbzNfS1RiNDUxak9OcXpPbUI1UTN5NDVSNlk2dEwyaHZxYnpzV1UzcDJ2SlppRzJJZw?oc=5","date":"2024-11-15","type":"deal","source":"GuruFocus","summary":"ARMISTICE CAPITAL, LLC Acquires New Stake in Trevena Inc - GuruFocus","headline":"ARMISTICE CAPITAL, LLC Acquires New Stake in Trevena Inc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFBNUkxQLXdfaXBZcXk1VmZITW1JMkpyNkluaURoM193cWpob3RLM0d1MnBuZ3RTTFZ5dzJ5RkdwUjJlUlMzemhPcDVNVDNQUlRKZlQ2cENYcVdlN1ZpSFJiZXQ1QXZ4YzlMVEhsWA?oc=5","date":"2024-11-13","type":"pipeline","source":"VISTA.Today","summary":"Chesterbrook-based Trevena Reduces Workforce, Continues to Evaluate Future Options - VISTA.Today","headline":"Chesterbrook-based Trevena Reduces Workforce, Continues to Evaluate Future Options","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQWlAzYkJid1JTZlBVYnJJQ2hNNE9fYjFHOTJRdTlUTVlaSHNNMU9IWTZwdS15R2dOaE0zSWpXcENNTHNuT1NJbTlOaG9YSU9pcVlCTVdIbXV1TFJmZG1nc0xWV2RPaGhMNkpHTjhJaGFZVkNsN3FxOWhiRVdEOFE2QURvWGdvdXZrbERLUVZJVXVWVnBOS2FRNGZnenNHWVJKMHpZcFFSMlRNdm9oUGtxaTBrSzlqeFhubURERzVYUW1sZnh3TGc?oc=5","date":"2024-11-07","type":"pipeline","source":"Fierce Biotech","summary":"Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review - Fierce Biotech","headline":"Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQWEI5bzNlM2R2SUF2bEtmOWRPRWZ3TkdJbWJLYlhDNDc5NUl4WlUyOTdoc0xrQ2V6b3ZKSVNlNmtWc3BLSVBLUXdVZkduYTZjTTg5SU5SWHNRS1FoTWRhUEtJT1pnTGg0R3FKQzh4M3dvX3pGX0VnaUxCMFBWTmFKOEJ1X242T3NzVnlxVWpybHB2aHktTEdFU2NvUXpzc1U2Rjg4aWNGMW93UjNmelpKYVlR?oc=5","date":"2024-11-07","type":"pipeline","source":"The Business Journals","summary":"Chester County biopharm firm's latest layoffs impact its C-suite - The Business Journals","headline":"Chester County biopharm firm's latest layoffs impact its C-suite","sentiment":"neutral"},{"date":"2024-11-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":0,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":0,"period":"2017-12-31"},{"value":0,"period":"2017-12-31"},{"value":0,"period":"2017-09-30"},{"value":0,"period":"2017-06-30"},{"value":0,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":16333000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-40289000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":40605000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}